Patents by Inventor Jan Powell

Jan Powell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CNS DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20230165942
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Application
    Filed: August 16, 2022
    Publication date: June 1, 2023
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • CNS delivery of therapeutic agents
    Patent number: 11471516
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 18, 2022
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • CNS DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20200113981
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Application
    Filed: September 17, 2019
    Publication date: April 16, 2020
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • CNS delivery of therapeutic agents
    Patent number: 10456454
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: October 29, 2019
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • CNS DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20170042978
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Application
    Filed: February 4, 2016
    Publication date: February 16, 2017
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • CNS delivery of therapeutic agents
    Patent number: 9283181
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Grant
    Filed: June 25, 2011
    Date of Patent: March 15, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • Methods for treating lysosomal acid lipase deficiency
    Patent number: 8945542
    Abstract: The present invention provides compositions and methods for effective treatment of a lysosomal acid lipase deficiency (LALD) disease, in particular, Wolman's disease and Cholesteryl Ester Storage Disease (CESD). Among other things, the present invention provides a method of treating developmental impairment or malnutrition in an individual suffering from a lysosomal acid lipase deficiency (LALD) disease, comprising administering to the individual a therapeutic effective amount of a lysosomal acid lipase.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: February 3, 2015
    Assignee: Synageva Biopharma Corp.
    Inventors: Michael Heartlein, Michael Concino, Paolo Martini, Muthuraman Meiyappan, Pericles Calias, Alla Romashko, Brian Pescatore, Lawrence Charnas, Jan Powell, Brian Felice, Nancy Savioli
  • METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY
    Publication number: 20140044697
    Abstract: The present invention provides compositions and methods for effective treatment of a lysosomal acid lipase deficiency (LALD) disease, in particular, Wolman's disease and Cholesteryl Ester Storage Disease (CESD). Among other things, the present invention provides a method of treating developmental impairment or malnutrition in an individual suffering from a lysosomal acid lipase deficiency (LALD) disease, comprising administering to the individual a therapeutic effective amount of a lysosomal acid lipase.
    Type: Application
    Filed: August 14, 2013
    Publication date: February 13, 2014
    Applicant: Synageva Biopharma Corp.
    Inventors: Michael Heartlein, Michael Concino, Paolo Martini, Muthuraman Meiyappan, Pericles Calias, Alla Romashko, Brian Pescatore, Lawrence Charnas, Jan Powell, Brian Felice, Nancy Savioli
  • CNS DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20120003202
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Application
    Filed: June 25, 2011
    Publication date: January 5, 2012
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh